Robert P. Byington, PhD
- Professor Emeritus, Epidemiology and Prevention, Public Health Sciences (Winston-Salem)

Robert P. Byington, PhD
- Positions
- Professor Emeritus, Epidemiology and Prevention, Public Health Sciences (Winston-Salem)
- Departments and Affiliations
- Epidemiology and Prevention, Public Health Sciences (Winston-Salem)
Research
- Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC, Fleg JL, Rosenberg Y, Byington RP. JAMA Cardiol. 2017 04; 2(4):370-380.
- Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial. Soliman EZ, Byington RP, Bigger JT, Evans G, Okin PM, Goff DC, Chen H. Hypertension. 2015 Dec; 66(6):1123-9.
- Fibroblast growth factor 23 and incident CKD in type 2 diabetes. Isakova T, Craven TE, Lee J, Scialla JJ, Xie H, Wahl P, Marcovina SM, Byington RP, Wolf M. Clin J Am Soc Nephrol. 2015 Jan; 10(1):29-38.
- Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Linz PE, Lovato LC, Byington RP, O'Connor PJ, Leiter LA, Weiss D, Force RW, Crouse JR, Ismail-Beigi F, Simmons DL, Papademetriou V, Ginsberg HN, Elam MB. Diabetes Care. 2014; 37(3):686-93.
- Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB. Diabetes Care. 2014; 37(3):634-43.